title: Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.
authors.forename: Su Ming Yvonne
authors.initials: SM
authors.lastname: Loh
authors.forename: Pavanni
authors.initials: P
authors.lastname: Ratnagopal
authors.forename: Huat Chye Patrick
authors.initials: HC
authors.lastname: Tan
authors.forename: Yeow Tee
authors.initials: YT
authors.lastname: Goh
authors.forename: Boon Chai Mickey
authors.initials: BC
authors.lastname: Koh
authors.forename: Liang Piu
authors.initials: LP
authors.lastname: Koh
authors.forename: Yeh Ching
authors.initials: YC
authors.lastname: Linn
authors.forename: William Ying Khee
authors.initials: WY
authors.lastname: Hwang
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000628:therapy*; D019653:Myeloablative Agonists / Q000008:administration & dosage*; D011034:Podophyllotoxin / Q000008:administration & dosage; D012074:Remission Induction; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D019653:Myeloablative Agonists; D003561:Cytarabine; D003520:Cyclophosphamide; D014740:Vidarabine; D011034:Podophyllotoxin; C024352:fludarabine; D008558:Melphalan; D002330:Carmustine